EUVIMEDEUVIMED entdecken
Open Access

Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder

William Wang, Nora D Volkow, QuangQiu Wang, Nathan A Berger, Pamela B Davis, David C Kaelber, Rong Xu

JAMA Network Open · 25.09.2024 · 7 (9) · e2435247

DOI: 10.1001/jamanetworkopen.2024.35247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 25.09.2024. Verfasst von William Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Opiate Overdose, Opioid-Related Disorders. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This cohort study uses emulation target trial methods to evaluate whether semaglutide is associated with lower rates of opioid overdose among patients with type 2 diabetes (T2D) and opioid use disorder (OUD).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesOpiate OverdoseOpioid-Related DisordersHumansFemaleMaleMiddle AgedHypoglycemic AgentsAdultSemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio.
  • National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland.
  • Laboratory of Neuroimaging, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland.
  • Center for Artificial Intelligence in Drug Discovery, Case Western Reserve University School of Medicine, Cleveland, Ohio.
  • Center for Community Health Integration, Case Western Reserve University School of Medicine, Cleveland, Ohio.
  • Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, Ohio.

Förderung

  • NCATS NIH HHS
  • NIA NIH HHS

Zitieren

APA

Wang, W., Volkow, N. D., Wang, Q., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024). Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder. JAMA Network Open, 7(9), e2435247. https://doi.org/10.1001/jamanetworkopen.2024.35247

Vancouver

Wang W, Volkow ND, Wang Q, Berger NA, Davis PB, Kaelber DC, et al. Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder. JAMA Network Open. 2024;7(9):e2435247. doi:10.1001/jamanetworkopen.2024.35247

BibTeX
@article{Wang2024,
  author = {Wang, William and Volkow, Nora D and Wang, QuangQiu and Berger, Nathan A and Davis, Pamela B and Kaelber, David C and Xu, Rong},
  title = {Semaglutide and Opioid Overdose Risk in Patients With Type 2 Diabetes and Opioid Use Disorder},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {9},
  pages = {e2435247},
  doi = {10.1001/jamanetworkopen.2024.35247}
}
Kostenlos starten →